array(12) { ["code"]=> string(5) "en_gb" ["id"]=> string(2) "64" ["native_name"]=> string(6) "Global" ["major"]=> string(1) "0" ["active"]=> string(1) "1" ["default_locale"]=> string(5) "en_GB" ["encode_url"]=> string(1) "0" ["tag"]=> string(5) "en-gb" ["translated_name"]=> string(6) "Global" ["url"]=> string(25) "https://www.prosigna.com/" ["country_flag_url"]=> string(0) "" ["language_code"]=> string(5) "en_gb" } native: Global
translated: Global
IN the US OUTSIDE the US
You are now entering a page intended for healthcare professionals only, if you are a patient or a member of the public, we will address you to a dedicated webpage.
Landmark OPTIMA Trial Delivers Practice-Changing Evidence that Veracyte’s Prosigna Test Identifies Patients with High-Risk Breast Cancer Who Can Safely Avoid Chemotherapy
Press Release OPTIMA Trial

THE TEST to answer more than one question

The breast cancer risk of recurrence test that confidently guides treatment decisions.